Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lineage Cell Therapeutics reports successful Q4, eyes strategic partnerships

Lineage Cell Therapeutics is advancing with promising programs like OpRegen, focusing on financial discipline and milestone achievements to drive shareholder value in 2023.
Despite net losses in 2022, Lineage's strong cash position, successful clinical outcomes, and strategic partnerships position the company for growth and leadership in cell therapy.

Lineage Cell Therapeutics reports progress in Q1 despite financial challenges

Lineage Cell Therapeutics showcased progress in OpRegen's clinical findings and financial performance in Q1 2023.
The company faces challenges in financials and market education but holds strengths in strategic partnerships and therapeutic advantages.
Opportunities lie in market positioning, collaborations, and continued innovation to drive growth and market adoption for Lineage's therapies.

Lineage Cell Therapeutics reports stable finances and advances key programs

Lineage Cell Therapeutics shows financial stability with strong cash reserves and a strategic focus on advancing key pipeline programs.
Despite challenges in patient enrollment and cell delivery, the company remains innovative and adaptable in exploring gene therapy solutions.
Positive FDA feedback on the OPC1 program and ongoing exploration of partnerships and advancements position Lineage for future growth and success.

Lineage Cell Therapeutics reports strong Q3 performance and eyes growth

Lineage Cell Therapeutics demonstrated financial stability, innovation in cell therapy, and progress in regenerative medicine programs during Q3 2023.
Challenges include study completion, safety concerns, enrollment trends, and strategic resource allocation for future growth.
Opportunities lie in market expansion, collaborations in neurology, therapeutic advancements, and regulatory success for the company.
Overall, Lineage Cell Therapeutics is positioned for growth through strategic partnerships and advancements in regenerative medicine.

Lineage Cell Therapeutics reports stable finances and program advancements

Lineage Cell Therapeutics showcased financial stability, program advancements, and strategic decisions in the Q4 2023 earnings call, emphasizing progress in OpRegen and OPC1 programs.
While facing challenges in managing expenses and uncertainties in program timelines, the company highlighted opportunities in partnerships, patient inclusion, and innovation for future growth.
Analyst questions focused on clinical outcomes, financing decisions, and program updates, reflecting investor interest in OpRegen program advancements and market potential.

Lineage Cell Therapeutics reports Q1 results, highlights partner support

Lineage Cell Therapeutics' Q1 2024 performance reflects revenue challenges but highlights strong partner support and operational preparedness.
The company faces financial losses amid investments in R&D but showcases a commitment to strategic growth and long-term success.
Challenges in revenue generation and data validation are balanced by opportunities in clinical trial efficiency, market demand, and therapeutic expansion.
Overall, Lineage's focus on innovation, partnerships, and operational readiness positions it for potential growth and success in the cell therapy space.

Lineage Cell Therapeutics extends cash runway, advances key programs

Lineage Cell Therapeutics reported financials for Q3 2024, extending cash runway and showcasing progress in key programs.
Strengths include advancements in OpRegen and ReSonance programs, with a strategic focus on manufacturing and partnerships.
Challenges lie in financial performance, maintaining cash discipline, and meeting study endpoints, while opportunities arise from collaborations and program advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address unmet medical needs, recently highlighted to members of the investment community its clinical and operational progress through a series of webinars hosted by FORCE Wealth with presentations by Brian M. Culley, Chief Executive Officer. The seminars covered all three of the company's clinical-stage product develop

Lineage Posts Series of Webinars Highlighting Recent Progress With its Three Clinical-Stage Allogeneic Cell Transplant Programs

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brandi Roberts, Chief Financial Officer, provided notice of her resignation on January 15th, 2021, in order to accept a leadership position at another company. Ms. Roberts has committed to providing consulting services to Lineage to ensure an orderly and smooth transition to th

Lineage Cell Therapeutics Announces Change to Executive Team

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. To Our Shareholders, As we reach the end of an eventful 2020, we are inspired by the many healthcare providers and biopharmaceutical companies that worked to combat the COVID-19 pandemic. This year has been difficult, but it has

Lineage Cell Therapeutics Provides End of Year Shareholder Letter

Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Lineage Cell Therapeutics (LCTX) Stock?

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious medical conditions, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the 13th Annual LD Micro Main Event virtual conference on December 14, 2020 at 12:00 pm Eastern Time / 9:00am Pacific Time. Interested investors can register and access the live presentation on the 13th Ann

Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1, its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI). The Company reported it has developed an enhanced differentiation process, leading to major improvements in production and quality of its OPC1 cel

Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury

Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and cancer-related conditions. Lineage's clinical pipeline is based around three programs OpRegen (Phase 1/2a) for AMD, OPC1 (Phase 2b/3) for SCI, and VAC2 (Phase 1) for NSCLC with a combined $40B potential market.

Lineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #DryAMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious medical conditions, today announced positive interim results from the ongoing 24-patient Phase 1/2a clinical study of Lineage's lead product candidate, OpRegen®. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for t

Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, strongly endorses the recent passing of Proposition 14 in California. This bill will enhance patients' access to groundbreaking stem cell therapy treatments by authorizing the California Institute for Regenerative Medicine (CIRM) the ability to fund up to $5.5 billion in grants to support therapeutic de

Lineage Cell Therapeutics Proudly Supports Patients' Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious conditions, today announced the successful completion of enrollment in its 24-patient Phase 1/2a study of its lead product candidate, OpRegen®. OpRegen is an investigational cell therapy consisting of retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-relat

Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript

Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2020. Lineage management will host a conference call today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2020 financial and operating results and to provide a business update. “Lineag

Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, will be hosting a call to discuss updated interim results from the Phase 1/2a study of its lead product candidate, OpRegen®, with one of the study's principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-relate

Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its third quarter 2020 financial and operating results on Wednesday, November 4, 2020, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time/1:30 p.m

Lineage Cell Therapeutics to Report Third Quarter 2020 Financial Results and Provide Business Update on November 4, 2020

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2020 American Academy of O

OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Meeting

CARLSBAD, Calif. & LONDON--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, today announced encouraging preliminary results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (NSCLC). VAC2 demonstrated remarkably potent induction of immune re

Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020

Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020

AgeX Therapeutics Inc

AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes

Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes

Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio

Lineage Cell Therapeutics Receives $24.6 Million Payment From Juvenescence Ltd.

Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2020 Results - Earnings Call Transcript

News for Lineage Cell Therapeutics Inc Stock (LCTX)